| Nov 1 |
Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
|
| Oct 31 |
Eli Lilly Earnings Have Wall Street Asking New Questions About GLP-1 Drugs. Is Something Going Wrong?
|
| Oct 31 |
Eli Lilly 'Well-Positioned' for Growth Into 2025 Despite Q3 Volatility, UBS Says
|
| Oct 31 |
Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings
|
| Oct 31 |
Eli Lilly and Company (NYSE:LLY): Among The 10 Best S&P 500 Stocks to Buy According to Hedge Funds
|
| Oct 31 |
Company News for Oct 31, 2024
|
| Oct 31 |
Eli Lilly core thesis ‘remains intact’ despite Q3 miss, says JPMorgan
|
| Oct 31 |
Meta, Microsoft AI Spending Is Causing Market Jitters. Why the Investing Won’t Stop and 5 Other Things to Know Today.
|
| Oct 31 |
Nasdaq Tumbles Over 100 Points Ahead Of Big Tech Earnings: Fear & Greed Index Remains In 'Greed' Zone
|
| Oct 31 |
Are Eli Lilly's Lowered Expectations a Reason to Sell?
|
